Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir : A Review in Chronic HCV Genotype 1 Infection
A fixed-dose tablet comprising ombitasvir (an NS5A replication complex inhibitor), paritaprevir (an NS3/4A protease inhibitor) and ritonavir (a cytochrome P450 inhibitor) taken in combination with dasabuvir (an NS5B polymerase inhibitor) is indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection in several countries, including the USA (copackaged as Viekira Pak(™)) and those of the EU (Viekirax(®) and Exviera(®)). In phase II and III trials, this interferon-free regimen, taken ± ribavirin, provided high rates of sustained virological response 12 weeks post-treatment in adults with chronic HCV genotype 1a or 1b infection, including those with compensated cirrhosis, liver transplants or HIV-1 co-infection. The regimen was generally well tolerated, with nausea, insomnia, asthenia, pruritus, other skin reactions and fatigue being among the most common tolerability issues. Thus, ombitasvir/paritaprevir/ritonavir plus dasabuvir is an effective interferon-free, direct-acting antiviral regimen for use ± ribavirin in a broad range of adults chronically infected with HCV genotype 1.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:75 |
|---|---|
| Enthalten in: |
Drugs - 75(2015), 9 vom: 14. Juni, Seite 1027-38 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Deeks, Emma D [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.04.2016 Date Revised 01.08.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1007/s40265-015-0412-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM249811642 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM249811642 | ||
| 003 | DE-627 | ||
| 005 | 20231224154403.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40265-015-0412-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0832.xml |
| 035 | |a (DE-627)NLM249811642 | ||
| 035 | |a (NLM)26059288 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Deeks, Emma D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir |b A Review in Chronic HCV Genotype 1 Infection |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.04.2016 | ||
| 500 | |a Date Revised 01.08.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a A fixed-dose tablet comprising ombitasvir (an NS5A replication complex inhibitor), paritaprevir (an NS3/4A protease inhibitor) and ritonavir (a cytochrome P450 inhibitor) taken in combination with dasabuvir (an NS5B polymerase inhibitor) is indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection in several countries, including the USA (copackaged as Viekira Pak(™)) and those of the EU (Viekirax(®) and Exviera(®)). In phase II and III trials, this interferon-free regimen, taken ± ribavirin, provided high rates of sustained virological response 12 weeks post-treatment in adults with chronic HCV genotype 1a or 1b infection, including those with compensated cirrhosis, liver transplants or HIV-1 co-infection. The regimen was generally well tolerated, with nausea, insomnia, asthenia, pruritus, other skin reactions and fatigue being among the most common tolerability issues. Thus, ombitasvir/paritaprevir/ritonavir plus dasabuvir is an effective interferon-free, direct-acting antiviral regimen for use ± ribavirin in a broad range of adults chronically infected with HCV genotype 1 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Anilides |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Carbamates |2 NLM | |
| 650 | 7 | |a Cyclopropanes |2 NLM | |
| 650 | 7 | |a Lactams, Macrocyclic |2 NLM | |
| 650 | 7 | |a Macrocyclic Compounds |2 NLM | |
| 650 | 7 | |a Sulfonamides |2 NLM | |
| 650 | 7 | |a ombitasvir |2 NLM | |
| 650 | 7 | |a 2302768XJ8 |2 NLM | |
| 650 | 7 | |a Uracil |2 NLM | |
| 650 | 7 | |a 56HH86ZVCT |2 NLM | |
| 650 | 7 | |a Proline |2 NLM | |
| 650 | 7 | |a 9DLQ4CIU6V |2 NLM | |
| 650 | 7 | |a 2-Naphthylamine |2 NLM | |
| 650 | 7 | |a CKR7XL41N4 |2 NLM | |
| 650 | 7 | |a dasabuvir |2 NLM | |
| 650 | 7 | |a DE54EQW8T1 |2 NLM | |
| 650 | 7 | |a Valine |2 NLM | |
| 650 | 7 | |a HG18B9YRS7 |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 650 | 7 | |a paritaprevir |2 NLM | |
| 650 | 7 | |a OU2YM37K86 |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs |d 1976 |g 75(2015), 9 vom: 14. Juni, Seite 1027-38 |w (DE-627)NLM00001611X |x 1179-1950 |7 nnns |
| 773 | 1 | 8 | |g volume:75 |g year:2015 |g number:9 |g day:14 |g month:06 |g pages:1027-38 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40265-015-0412-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 75 |j 2015 |e 9 |b 14 |c 06 |h 1027-38 | ||